TimesSquare Capital Management’s Tarsus Pharmaceuticals TARS Stock Holding History

TimesSquare Capital Management’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$27.3M	Buy	388,590 +56,144	+17%	+$3.92M	0.46%	82
2025 Q4	$27.2M	Buy	332,446 +64,941	+24%	+$4.85M	0.41%	96
2025 Q3	$15.9M	Buy	+267,505	New	+$13.2M	0.23%	132
2023 Q2	–	Sell	-1,192,660	Closed	-$15M	–	187
2023 Q1	$15M	Sell	1,192,660 -236,650	-17%	-$3.46M	0.22%	143
2022 Q4	$21M	Sell	1,429,310 -90,600	-6%	-$1.5M	0.3%	129
2022 Q3	$26M	Buy	1,519,910 +38,200	+3%	+$607K	0.36%	125
2022 Q2	$21.6M	Buy	1,481,710 +822,110	+125%	+$12.3M	0.3%	131
2022 Q1	$11.1M	Sell	659,600 -1,200	-0.2%	-$22.3K	0.12%	167
2021 Q4	$14.9M	Buy	660,800 +10,020	+2%	+$261K	0.13%	175
2021 Q3	$14M	Sell	650,780 -35,925	-5%	-$889K	0.12%	192
2021 Q2	$19.9M	Buy	686,705 +234,805	+52%	+$7.33M	0.16%	180
2021 Q1	$14.6M	Sell	451,900 -12,700	-3%	-$470K	0.12%	186
2020 Q4	$19.2M	Buy	+464,600	New	+$13.2M	0.16%	181

Other funds holding TARS

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

TimesSquare Capital Management's TARS Position: Q1 2026 in Review

TimesSquare Capital Management increased its Tarsus Pharmaceuticals (TARS) stake by 17% in Q1 2026, buying an estimated $3.92M and bringing the position to 388,590 shares worth $27.3M. The position accounts for 0.46% of the portfolio, ranked #82.

TimesSquare Capital Management first reported a position in TARS in Q4 2020 and has held it in 13 quarters since. 253 funds tracked by Wall St. Rank hold TARS as of Q1 2026.

TimesSquare Capital Management held 388,590 shares of Tarsus Pharmaceuticals worth $27.3M as of Q1 2026.
TimesSquare Capital Management bought 56,144 Tarsus Pharmaceuticals shares in Q1 2026, an estimated $3.92M.
Tarsus Pharmaceuticals made up 0.46% of TimesSquare Capital Management's portfolio in Q1 2026, its #82 holding.
TimesSquare Capital Management first reported a position in Tarsus Pharmaceuticals in Q4 2020 and has held it in 13 quarters since.
253 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2026.

Based on TimesSquare Capital Management's 13F filing for Q1 2026, filed 7 May 2026.